- RecruitingPhase II
SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.
This trial tests whether targeted, pinpoint radiotherapy can help control ovarian cancer that has grown in just a few small spots after drug treatment. Patients receive radiotherapy to the growing tumours, either on its own or followed by a daily targeted tablet called niraparib, to delay further cancer progression.
For: Oligometastatic or oligoprogressive ovarian, fallopian tube or primary peritoneal carcinomaUnited Kingdom · England · Scotland - Active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
This study is testing a new combination of medicines, niraparib and abiraterone, with prednisone, for men with advanced prostate cancer that has spread and is resistant to hormone therapy. It compares this new combination against the standard treatment of abiraterone and prednisone to see if it works better.
For: Castration-Resistant Prostatic CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study is looking at a new medicine called Niraparib to see if it can help women with advanced ovarian cancer stay well for longer after their first round of chemotherapy. It’s comparing Niraparib to a dummy drug (placebo).
For: Ovarian NeoplasmsUnited States · Belgium · Denmark - RecruitingPHASE2
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
This study looks at adding a drug called niraparib to regular immunotherapy for people with a specific type of advanced small cell lung cancer (SCLC). It aims to see if this addition helps control the cancer better after initial treatment.
For: SCLC,Extensive Stage · SLFN11-positiveFrance · Germany · Italy - RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom - Active not recruitingPHASE1
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
This study is testing new ways to give medicines called niraparib and abiraterone acetate for men with advanced prostate cancer. Researchers want to see how well different forms of these drugs are absorbed by the body to help patients get the best treatment.
For: Prostatic NeoplasmsUnited States · Belgium · France - RecruitingPHASE2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
This study looks at new ways to treat advanced breast cancer that has stopped responding to standard treatments. By checking your blood or tumour for specific signs, doctors hope to find the best treatment for you, exploring several new drugs and combinations.
For: Breast CancerCanada - Active not recruitingPHASE3
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
This study looks at a new drug, Niraparib, for certain types of breast cancer: HER2-negative with a faulty BRCA gene or triple-negative breast cancer. It investigates if Niraparib is better than a dummy pill (placebo) after surgery or standard treatment.
For: Neoplasms, BreastUnited States · Argentina · Australia - Active not recruitingPHASE2
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
This study is for women with ovarian cancer that has come back after treatment with certain drugs (PARP inhibitors). It's looking at new combinations of medicines (tuvusertib with niraparib or lartesertib) to see how well they work and if they are safe.
For: Ovarian CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
This study looks at new ways to treat advanced or returning womb cancer. It compares a drug called dostarlimab, with or without another drug called niraparib, alongside standard chemotherapy, against chemotherapy plus a dummy drug, to see if these new treatments work better and are safe.
For: NeoplasmsUnited States · Belarus · Belgium - RecruitingPHASE3
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
This study compares two ways to treat advanced ovarian cancer: standard chemotherapy plus a medicine called niraparib, versus standard chemotherapy plus two medicines, bevacizumab and niraparib. It aims to see which treatment works best to control the cancer.
For: Ovarian Cancer · Fallopian Tube Cancer · Peritoneal CancerGermany - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
For: CancerUnited States · Australia · Belgium - RecruitingPHASE2
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
This study looks at different ways to give a drug called niraparib to women with advanced ovarian cancer. It aims to find out if changing the dose helps reduce side effects while still being an effective treatment after chemotherapy.
For: Ovarian Cancer · Stage III Ovarian Cancer · Stage IV Ovarian CancerCanada - Active not recruitingPHASE3
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
This study compares new drug combinations (dostarlimab and niraparib) with standard care for women newly diagnosed with advanced ovarian cancer. It aims to see if these new treatments can stop the cancer from growing for longer.
For: Ovarian Neoplasms · Ovarian, Fallopian Tube and Primary Peritoneal CarcinomaUnited States · Belarus · Belgium - Active not recruitingPHASE1
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
This early-stage study is testing a new drug called Tuvusertib (M1774), alone or with another drug called niraparib, for people with advanced solid tumours that have spread or can't be removed by surgery. Doctors want to see if it's safe, how the body handles it, and if it shows any early signs of helping.
For: Metastatic or Locally Advanced Unresectable Solid TumorsUnited States · China · Japan - Active not recruitingPHASE3
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
This study compares a new drug (niraparib) with standard treatment (temozolomide) for a type of brain tumour called glioblastoma. We want to see if niraparib can help people live longer. Participants will take medication daily alongside radiotherapy.
For: Glioblastoma · GBM · Brain Neoplasms, Adult, MalignantUnited States · Australia · Canada